胰腺癌微生物组通过诱导固有和适应性免疫抑制促进肿瘤发生
在小鼠和人类中,癌性胰腺的微生物组显著多于正常胰腺,且肿瘤胰腺中特定细菌较肠道差异增加。消融微生物组可预防浸润前和浸润性胰腺导管腺癌(PDA),而转移PDA宿主而非对照的细菌可逆转肿瘤保护。细菌消融与PDA肿瘤微环境的免疫原性重编程相关,包括减少髓源性抑制细胞和增加M1巨噬细胞分化,促进CD4+ T细胞的TH1分化和CD8+ T细胞活化。细菌消融还通过上调PD-1表达使检查点靶向免疫治疗有效。机制上,PDA微生物组通过在单核细胞中差异激活特定Toll样受体产生耐受性免疫程序。
要点
- 癌性胰腺微生物组较正常胰腺显著丰富,特定细菌在肿瘤胰腺中差异增加。
- 消融微生物组可预防PDA,转移PDA宿主细菌可逆转肿瘤保护。
- 细菌消融重编程肿瘤微环境并上调PD-1使免疫治疗有效。
核心结论
- 内源性微生物组促进PDA的免疫抑制特征,微生物组有潜力作为治疗靶点调节疾病进展。
研究设计与样本
- 研究在小鼠和人类中比较癌性与正常胰腺的微生物组,并进行了微生物组消融和细菌转移实验。
主要发现
- 癌性胰腺微生物组较正常胰腺显著更丰富,特定细菌在肿瘤胰腺中差异增加。
- 消融微生物组可预防浸润前和浸润性PDA,转移PDA宿主细菌逆转肿瘤保护。
- 细菌消融减少髓源性抑制细胞、增加M1巨噬细胞分化,促进TH1分化和CD8+ T细胞活化。
- 细菌消融通过上调PD-1表达使检查点靶向免疫治疗有效。
- PDA微生物组通过差异激活单核细胞中特定Toll样受体产生耐受性免疫程序。
临床怎么用
- 靶向微生物组可能预防肿瘤发生、逆转瘤内免疫耐受并使检查点免疫治疗有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We found that the cancerous pancreas harbors a markedly more abundant microbiome compared with normal pancreas in both mice and humans, and select bacteria are differentially increased in the tumorous pancreas compared with gut. Ablation of the microbiome protects against preinvasive and invasive pancreatic ductal adenocarcinoma (PDA), whereas transfer of bacteria from PDA-bearing hosts, but not controls, reverses tumor protection. Bacterial ablation was associated with immunogenic reprogramming of the PDA tumor microenvironment, including a reduction in myeloid-derived suppressor cells and an increase in M1 macrophage differentiation, promoting TH1 differentiation of CD4+ T cells and CD8+ T-cell activation. Bacterial ablation also enabled efficacy for checkpoint-targeted immunotherapy by upregulating PD-1 expression. Mechanistically, the PDA microbiome generated a tolerogenic immune program by differentially activating select Toll-like receptors in monocytic cells. These data suggest that endogenous microbiota promote the crippling immune-suppression characteristic of PDA and that the microbiome has potential as a therapeutic target in the modulation of disease progression.Significance: We found that a distinct and abundant microbiome drives suppressive monocytic cellular differentiation in pancreatic cancer via selective Toll-like receptor ligation leading to T-cell anergy. Targeting the microbiome protects against oncogenesis, reverses intratumoral immune tolerance, and enables efficacy for checkpoint-based immunotherapy. These data have implications for understanding immune suppression in pancreatic cancer and its reversal in the clinic. Cancer Discov; 8(4); 403-16. ©2018 AACR.See related commentary by Riquelme et al., p. 386This article is highlighted in the In This Issue feature, p. 371.
引用
- Pushalkar S, Hundeyin M, Daley D, et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018. PMID: 29567829. doi:10.1158/2159-8290.CD-17-1134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。